BMJ Group: Trial Assesses Safety and Effectiveness of Two New TB Vaccines
10 April 2026
BMJ Group news release
Two new vaccines to prevent TB are safe for use in adults and children, but they do not offer protection against all forms of TB, finds a large trial from India published in The BMJ.
Researchers in India conducted a large trial to evaluate whether two new TB vaccines (VPM1002 and Immuvac) can protect against all forms of TB (pulmonary and extrapulmonary), prevent latent (dormant) infection, and generate an immune response against the TB bacterium.
The study enrolled 12,717 household contacts (aged 6 years and older) of recently diagnosed TB patients across 18 sites in six Indian states between July 2019 and December 2020.
Read the full news release here.
Source: BMJ Group
SEE ALSO:
- Gavi/VaccinesWork: Two New TB Vaccine Candidates Show Promise but Fail to Stop Infection
- CIDRAP: TB Vaccine Candidates Offer Limited Protection in Phase 3 Trial
